REGENXBIO Posts $0.62 Per-Share Q3 Loss as FDA Hold Weighs on Gene Therapy Pipeline
RGNX sits 47% above its 52-week low of $5.455.
Summary
REGENXBIO reported a third-quarter loss of $40.7 million, or $0.62 per share, per Dow Jones, on revenue of $9.2 million. That follows a rough stretch: the FDA placed a clinical hold on the Hunter syndrome gene therapy RGX-121 in late August, and management said it does not expect to resubmit the BLA in the near term. The company did bank $39.0 million in cash in September by settling all ELEVIDYS patent litigation with Sarepta, which helps offset the cash burn. With a small market cap and a going-concern-flagged ATM already in place, the size of this quarterly loss relative to the balance sheet is the number that matters. Watch for the full 10-Q and any update on cash runway, which now extends into late Q4 2027.
At the time of this announcement, RGNX was trading at $8.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $509M. The 52-week trading range was $5.46 to $16.19. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.